A Study to Evaluate Efficacy and Safety of Hydeal Cyst® Intravesical Instillations in Patients Treated With Intravesical Chemotherapy or Immunotherapy in Non-muscle Invasive Bladder Cancer

Prior to performing any study specific procedure (including screening procedures to determine eligibility), a signed consent form will be obtained for each subject. Patients will be enrolled in the study only if they meet all the inclusion criteria and none of the exclusion criteria. Prior to perform any study specific procedure (including screening procedures to determine eligibility), a signed informed consent form will be obtained for each subject. The informed consent form will describe the purpose of the study, the procedures to be followed, and the risk and benefits of participation. Th

Trial Details

NCT ID
NCT06245603
Phase
NA
Sponsor
Istituto Oncologico Veneto IRCCS
Status
RECRUITING
Cancer Type
Non-Muscle-Invasive Bladder Cancer
Interventions
  • Hydeal Cyst®
Locations (sample)
  • Bergamo, Italy|45.69601,9.66721
  • Bologna, Italy|44.49381,11.33875
  • Foggia, Italy|41.45845,15.55188
  • Padova, Italy|44.38225,11.14261
  • Padova, Italy|44.38225,11.14261

Key Eligibility Criteria

  • Male or female ≥ 18 years of age
  • ECOG PS 0-2
  • Histologically confirmed diagnosis of non-muscle invasive bladder cancer, naïve and recurrent.
  • Patients candidate to BCG or MMC intravesical induction therapy.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Muscle-Invasive Bladder Cancer Trials on Trialify →